Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Monday. $58.18 million flowed into the stock on the tick-up and $119.13 million flowed out of the stock on the tick-down, for a money net flow of $60.95 million out of the stock. Of all equities tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.29 for the day and closed at $35.11

PFE has been the subject of several analyst reports. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 22nd. Jefferies Group set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, August 25th. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Finally, JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $38.82.

The stock’s 50 day moving average is $35.81 and its 200 day moving average is $33.38. The firm has a market cap of $212.97 billion and a PE ratio of 31.13.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the previous year, the company earned $0.56 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.42%.

A number of hedge funds have recently added to or reduced their stakes in PFE. Holderness Investments Co. raised its stake in Pfizer by 0.8% in the fourth quarter. Holderness Investments Co. now owns 65,817 shares of the biopharmaceutical company’s stock valued at $2,125,000 after buying an additional 550 shares in the last quarter. Novare Capital Management LLC raised its stake in Pfizer by 0.8% in the fourth quarter. Novare Capital Management LLC now owns 204,262 shares of the biopharmaceutical company’s stock valued at $6,594,000 after buying an additional 1,590 shares in the last quarter. Mycio Wealth Partners LLC raised its stake in Pfizer by 5.8% in the fourth quarter. Mycio Wealth Partners LLC now owns 33,436 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,825 shares in the last quarter. Pettyjohn Wood & White Inc. raised its stake in Pfizer by 2.7% in the fourth quarter. Pettyjohn Wood & White Inc. now owns 83,918 shares of the biopharmaceutical company’s stock valued at $2,709,000 after buying an additional 2,200 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in Pfizer by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 794,289 shares of the biopharmaceutical company’s stock valued at $25,640,000 after buying an additional 3,766 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.